Showing 227 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

South African firms lose out on lenacapavir production

Editor's pick
Juta MedicalBrief
23 October 2025
Pharmaceutical industry

HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price

Editor's pick
Infectious Disease Society of America
21 October 2025
PrEP policies & guidelines

NICE approves annual access to injectable cabotegravir PrEP in England for 1000 people

Editor's pick
i-Base
17 October 2025
PrEP policies & guidelines

NHS to roll out first long-acting injection to prevent HIV

Editor's pick
NHS England
17 October 2025
Injectable & long-acting PrEP

The six-monthly anti-HIV jab is coming. But can South Africa keep track of millions of users?

Editor's pick
Bhekisisa
9 October 2025
PrEP science

Cabotegravir PrEP Implant Might Prevent HIV for a Year

Editor's pick
POZ
2 October 2025
PrEP policies & guidelines

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily HIV prevention pill

Editor's pick
Bhekisisa
24 September 2025
Injectable & long-acting PrEP

Support for Indian Manufacturers to Produce Cheap Generics of HIV ‘Miracle’ Drug, Lenacapavir

Editor's pick
Health Policy Watch
24 September 2025
Injectable & long-acting PrEP

From Bench to Breakthrough: How Curiosity Led to an Extraordinarily Effective HIV Drug

Editor's pick
University of Utah
24 September 2025
Injectable & long-acting PrEP

CDC 'strongly' backs Gilead's HIV PrEP Yeztugo, but advocacy groups say access barriers remain

Editor's pick
FiercePharma
23 September 2025
Injectable & long-acting PrEP

Can health systems keep pace with HIV prevention’s breakthrough?

Editor's pick
Devex (requires free registration)
15 September 2025
Injectable & long-acting PrEP

Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug

Editor's pick
NPR
5 September 2025
Injectable & long-acting PrEP

US: CVS Will Not Cover Long-Acting HIV PrEP Lenacapavir For Now

Editor's pick
POZ
5 September 2025
Injectable & long-acting PrEP

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Editor's pick
Gilead Sciences press release
5 September 2025
Injectable & long-acting PrEP

Twists and turns in the race to be South Africa’s first widely used HIV prevention injection

Editor's pick
Spotlight
4 September 2025
Injectable & long-acting PrEP

Kenya to roll out HIV jab lenacapavir in 2026, not a replacement for anti-retrovirals

Editor's pick
Africa Check
4 September 2025
Injectable & long-acting PrEP

South Africa plans anti-HIV jab roll-out at 300+ clinics by April

Editor's pick
Bhekisisa
28 August 2025
Injectable & long-acting PrEP

EU approves Gilead's new injection for preventing HIV

Editor's pick
Reuters
28 August 2025
Injectable & long-acting PrEP

The EXPrESSIVE Trials Test a Monthly Pill for PrEP: Advocates speak

Editor's pick
AVAC
25 August 2025
PrEP policies & guidelines

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

Editor's pick
FiercePharma
25 August 2025
Injectable & long-acting PrEP

We Have More PrEP Options Than Ever In The U.S.—But Who Will Be Able To Afford Them?

Editor's pick
TheBody
25 August 2025
Injectable & long-acting PrEP

Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions

News
30 July 2025
Injectable & long-acting PrEP

EMA recommendation on new injection for easier prevention of HIV in the EU and worldwide

Editor's pick
European Medicines Agency
26 July 2025
Injectable & long-acting PrEP

South Africa gets R520-million to buy the twice-a-year anti-HIV jab — but there’s a snag

Editor's pick
Bhekisisa
24 July 2025